Scopus BioPharma Inc.

SCPS

US8091711015

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:30:23 2024-05-08 am EDT			5-day change	1st Jan Change
0.0021 ^USD	+90.91%		+90.91%	-95.13%

2023	Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	CI
2023	Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022

May 13, 2022 at 05:16 pm EDT

Scopus BioPharma Inc. announced resignation of Ashish Sanghrajka from the Board of Directors with effect from May 11, 2022.

Latest news about Scopus BioPharma Inc.

Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	Nov. 07	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
Scopus BioPharma Inc.(NasdaqCM:SCPS) dropped from S&P TMI Index	22-12-21	CI
Scopus BioPharma Inc.(NasdaqGM:SCPS) dropped from NASDAQ Composite Index	22-12-16	CI
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower	22-12-15	MT
Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move Lower	22-12-15	MT
Top Premarket Gainers	22-12-15	MT
Scopus BioPharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Top Premarket Decliners	22-07-11	MT
Scopus BioPharma Inc. Announces Resignation of Paul Hopper from Board of Directors	22-05-20	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-19	CI
Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022	22-05-13	CI
Scopus BioPharma Inc. Appoints Raphael Hofstein to its Board of Directors	22-05-05	CI
Scopus Biopharma Inc. Announces Board Resignations	22-04-29	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Scopus BioPharma Announces the Final Results	22-01-10	CI
Scopus BioPharma Inc. Announces Board Appointments	22-01-06	CI
Declaration of Preliminary Voting Results by Scopus BioPharma	21-12-27	CI
Scopus BioPharma Sends Letter to its Shareholders	21-12-17	CI
Scopus BioPharma Sends Letter to its Shareholders	21-12-07	CI

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Companyâs Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCOPUS BIOPHARMA INC.	-95.13%	88.38K
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-1.89%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs